TargetBeta
HDAC9
histone deacetylase 9 · also KIAA0744, HDAC, MITR, HD7 · Histone deacetylases, class IIA
2 programs in company-led studies act on HDAC9, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| givinostatrule | Italfarmaco | phase 3 | 234 running | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8 | ChEMBL |
| givinostat hydrochloriderule | Italfarmaco | phase 2 | 11 running | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8 | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Muscular Dystrophy, Duchenne, 2 programs
- Arthritis, Juvenile, 1 program
- Hodgkin Disease, 1 program
- Myeloproliferative Disorders, 1 program
- Polycythemia Vera, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026givinostat · Italfarmaco · phase 3 · NCT01761968
- Dec 2029givinostat hydrochloride · Italfarmaco · phase 2 · NCT06769633
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.